SCHEMBL14830222

SCHEMBL14830222

COc1ccc(COCC[C@@H](C)O)cc1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.53
ALDH1A1 P00352 5/20 0.49
CA2 P00918 1/20 0.49
TSHR P16473 2/20 0.47
HTT P42858 1/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47
LDHA P00338 1/20 0.46
ADRB2 P07550 2/20 0.45
LMNA P02545 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
SLC22A1 O15245 1/20 0.45
CHRM2 P08172 1/20 0.45
ADRB1 P08588 1/20 0.45
CYP3A4 P08684 1/20 0.45
CHRM1 P11229 1/20 0.45
NFKB1 P19838 1/20 0.45
SLC6A4 P31645 1/20 0.45
OPRM1 P35372 1/20 0.45
SLC6A3 Q01959 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15236787 0.80 STAT3 (0.73) STAT3CA2LDHACYP3A4ABCB1
SCHEMBL318036 0.79 CA2 (0.68) STAT3ALDH1A1CA2LDHACYP3A4
SCHEMBL29475007 0.79 CA2 (0.68) STAT3ALDH1A1CA2LDHACYP3A4
SCHEMBL7959717 0.78 CA2 (0.57) STAT3ALDH1A1CA2TSHRHTT
SCHEMBL15259646 0.78 CALM1 (0.50) ALDH1A1CA2TSHRKDM4E
SCHEMBL31512861 0.77 FOS (0.58) ALDH1A1TSHRALOX15ALOX12ADRB2
SCHEMBL580129 0.77 FOS (0.58) ALDH1A1TSHRALOX15ALOX12ADRB2
SCHEMBL21402273 0.77 ALOX15 (0.58) TSHRALOX15ALOX12LMNACYP3A4
SCHEMBL4387213 0.76 ALDH1A1 (0.42) STAT3ALDH1A1CA2TSHRHTT
SCHEMBL4598867 0.76 LDHA (0.64) STAT3ALDH1A1CA2HTTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760845-A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2014-08-06 EP disclosed
WO-2013049250-A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2013-04-04 WO disclosed